An immunohistochemical evaluation of androgen and progesterone receptors in ovarian tumors. 1993

S Chadha, and B R Rao, and B J Slotman, and C C van Vroonhoven, and T H van der Kwast
Department of Pathology, University Hospital, Dijkzigt, The Netherlands.

To visualize the heterogeneity of androgen receptor (AR) and progesterone receptor (PR) expression in ovarian tumors, 61 specimens were studied immunohistochemically using specific mouse monoclonal antibodies. The tested ovarian tumors included ovarian carcinomas of serous, mucinous, endometrioid, undifferentiated, and clear cell types as well as borderline epithelial tumors, mucinous cystadenomas, granulosa cell tumors, metastatic ovarian tumors, and one case of immature teratoma. Sixty-seven percent of ovarian carcinomas expressed AR, while 46% of the ovarian carcinomas expressed PR. In addition, the three tested borderline epithelial tumors were AR positive. Androgen receptor and PR were primarily localized in the nuclei of ovarian tumor cells. In three tumors focal staining of intervening stroma cells was observed. Interestingly, 35 of the granulosa cell tumors expressed PR as well as AR. All tumor types displayed a wide range in their proportions of AR- and PR-positive tumor cells. A poor correlation, however, was observed when semiquantitative immunohistochemical AR staining results on 17 ovarian carcinomas were compared with biochemical cytosol AR estimations using the dextran-coated charcoal method. Our study indicates that AR as well as PR is expressed by a substantial proportion of ovarian borderline and malignant tumors and that there is a strong heterogeneity in expression of AR and PR. It is possible to evaluate the prognostic significance of these receptors in ovarian cancers on fresh-frozen tumor specimens using a simple immunohistochemical technique.

UI MeSH Term Description Entries
D007124 Immunoenzyme Techniques Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens. Antibody Enzyme Technique, Unlabeled,Enzyme Immunoassay,Enzyme-Labeled Antibody Technique,Immunoassay, Enzyme,Immunoperoxidase Techniques,Peroxidase-Antiperoxidase Complex Technique,Peroxidase-Labeled Antibody Technique,Antibody Enzyme Technic, Unlabeled,Enzyme-Labeled Antibody Technic,Immunoenzyme Technics,Immunoperoxidase Technics,Peroxidase-Antiperoxidase Complex Technic,Peroxidase-Labeled Antibody Technic,Antibody Technic, Enzyme-Labeled,Antibody Technic, Peroxidase-Labeled,Antibody Technics, Enzyme-Labeled,Antibody Technics, Peroxidase-Labeled,Antibody Technique, Enzyme-Labeled,Antibody Technique, Peroxidase-Labeled,Antibody Techniques, Enzyme-Labeled,Antibody Techniques, Peroxidase-Labeled,Enzyme Immunoassays,Enzyme Labeled Antibody Technic,Enzyme Labeled Antibody Technique,Enzyme-Labeled Antibody Technics,Enzyme-Labeled Antibody Techniques,Immunoassays, Enzyme,Immunoenzyme Technic,Immunoenzyme Technique,Immunoperoxidase Technic,Immunoperoxidase Technique,Peroxidase Antiperoxidase Complex Technic,Peroxidase Antiperoxidase Complex Technique,Peroxidase Labeled Antibody Technic,Peroxidase Labeled Antibody Technique,Peroxidase-Antiperoxidase Complex Technics,Peroxidase-Antiperoxidase Complex Techniques,Peroxidase-Labeled Antibody Technics,Peroxidase-Labeled Antibody Techniques,Technic, Enzyme-Labeled Antibody,Technic, Immunoenzyme,Technic, Immunoperoxidase,Technic, Peroxidase-Antiperoxidase Complex,Technic, Peroxidase-Labeled Antibody,Technics, Enzyme-Labeled Antibody,Technics, Immunoenzyme,Technics, Immunoperoxidase,Technics, Peroxidase-Antiperoxidase Complex,Technics, Peroxidase-Labeled Antibody,Technique, Enzyme-Labeled Antibody,Technique, Immunoenzyme,Technique, Immunoperoxidase,Technique, Peroxidase-Antiperoxidase Complex,Technique, Peroxidase-Labeled Antibody,Techniques, Enzyme-Labeled Antibody,Techniques, Immunoenzyme,Techniques, Immunoperoxidase,Techniques, Peroxidase-Antiperoxidase Complex,Techniques, Peroxidase-Labeled Antibody
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011944 Receptors, Androgen Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA. Androgen Receptors,5 alpha-Dihydrotestosterone Receptor,Androgen Receptor,Dihydrotestosterone Receptors,Receptor, Testosterone,Receptors, Androgens,Receptors, Dihydrotestosterone,Receptors, Stanolone,Stanolone Receptor,Testosterone Receptor,5 alpha Dihydrotestosterone Receptor,Androgens Receptors,Receptor, 5 alpha-Dihydrotestosterone,Receptor, Androgen,Receptor, Stanolone,Stanolone Receptors,alpha-Dihydrotestosterone Receptor, 5
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D003537 Cystadenoma A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed) Cystadenomas
D005260 Female Females
D006106 Granulosa Cell Tumor A neoplasm composed entirely of GRANULOSA CELLS, occurring mostly in the OVARY. In the adult form, it may contain some THECA CELLS. This tumor often produces ESTRADIOL and INHIBIN. The excess estrogen exposure can lead to other malignancies in women and PRECOCIOUS PUBERTY in girls. In rare cases, granulosa cell tumors have been identified in the TESTES. Cancer of Granulosa Cells,Granulosa Cell Cancer,Cancer, Granulosa Cell,Cancers, Granulosa Cell,Cell Cancer, Granulosa,Cell Cancers, Granulosa,Cells Cancer, Granulosa,Cells Cancers, Granulosa,Granulosa Cell Cancers,Granulosa Cell Tumors,Granulosa Cells Cancer,Granulosa Cells Cancers,Tumor, Granulosa Cell,Tumors, Granulosa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S Chadha, and B R Rao, and B J Slotman, and C C van Vroonhoven, and T H van der Kwast
June 1998, Journal of experimental & clinical cancer research : CR,
S Chadha, and B R Rao, and B J Slotman, and C C van Vroonhoven, and T H van der Kwast
January 2009, Brazilian oral research,
S Chadha, and B R Rao, and B J Slotman, and C C van Vroonhoven, and T H van der Kwast
March 2000, Journal of clinical pathology,
S Chadha, and B R Rao, and B J Slotman, and C C van Vroonhoven, and T H van der Kwast
September 2000, European journal of cancer (Oxford, England : 1990),
S Chadha, and B R Rao, and B J Slotman, and C C van Vroonhoven, and T H van der Kwast
February 1998, British journal of obstetrics and gynaecology,
S Chadha, and B R Rao, and B J Slotman, and C C van Vroonhoven, and T H van der Kwast
April 1995, Journal of cutaneous pathology,
S Chadha, and B R Rao, and B J Slotman, and C C van Vroonhoven, and T H van der Kwast
June 2004, Molecular and cellular endocrinology,
S Chadha, and B R Rao, and B J Slotman, and C C van Vroonhoven, and T H van der Kwast
October 1983, Gynecologic oncology,
S Chadha, and B R Rao, and B J Slotman, and C C van Vroonhoven, and T H van der Kwast
January 2004, Voprosy onkologii,
S Chadha, and B R Rao, and B J Slotman, and C C van Vroonhoven, and T H van der Kwast
July 2007, The Journal of veterinary medical science,
Copied contents to your clipboard!